Astellas Pharma ends development of dust mite allergy vaccine

Astellas Pharma will book an impairment loss of just under USD 400m due to three less-than-successful drug programs. One of the programs, concerning a DNA vaccine against dust mite-induced allergic rhinitis, has now been terminated.

Photo: Kim Kyung-Hoon/Reuters/Ritzau Scanpix

Japanese Astellas Pharma has been less than fortunate when it comes to its clinical development programs.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs